Chitrakar N S
Department of Gynecology and Obstetrics, Paropakar Maternity and Women's Hospital, Kathmandu, Nepal.
J Nepal Health Res Counc. 2012 Jan;10(1):10-5.
The purpose of this study was to compare the efficacy and safety of 25 μg Misoprostol vs. 0.5 mg Dinoprostone for pre-labour ripening of the cervix at-term.
Nullipara or Para one women with unfavourable cervices after 37 completed weeks with live foetuses were randomized to received either 25 μg intravaginal Misoprostol or 0.5 mg intracervical Dinoprostone. The doses were repeated after 6 hrs if the Bishop Score was less than 6. In cases, in which cervical ripening was not reached even after two doses of ripening agents, oxytocin induction was started at least 6 hours apart. Insertion delivery interval (IDI), complications and pregnancy outcome associated with the use of drugs were compared.
Two hundred women--100 in each group were evaluated. Comparatively more women (62% vs. 58%) in the Misoprostol group achieved cervical ripening (BS≥6) after one dose. The mean IDI was significantly shorter (3.91 hrs) in the Misoprostol group. The difference was marked more among the multipara at 5.72 hrs, mean difference (p=0.045). In the Misoprostol group 76.92% delivered within 24 hrs whereas, only 70.4% in the Dinoprostone group. Vaginal deliveries were achieved more in the Misoprostol group (78% vs. 71%). No significant differences found in terms of intrapartum complications and foetal outcome. Meconium stained liquor was found more in the Dinoprostone group (23% vs. 32%).
A 25 μg dose of Misoprostol is superior in promoting cervical ripening, significantly shortened the insertion delivery interval. It is safe and effective for cervical ripening when applied in the hospital setting with close monitoring.
本研究旨在比较25μg米索前列醇与0.5mg地诺前列酮用于足月妊娠前促宫颈成熟的疗效和安全性。
孕周满37周、宫颈条件不佳的初产妇或经产妇且胎儿存活者被随机分为两组,分别接受25μg阴道内给予米索前列醇或0.5mg宫颈内给予地诺前列酮。若Bishop评分小于6分,则在6小时后重复给药。若两剂促宫颈成熟药物后仍未达到宫颈成熟,则至少间隔6小时开始催产素引产。比较用药后的引产至分娩间隔(IDI)、并发症及妊娠结局。
共评估200名女性,每组100名。米索前列醇组单次给药后达到宫颈成熟(Bishop评分≥6分)的女性相对较多(62%对58%)。米索前列醇组的平均IDI显著更短(3.91小时)。经产妇中的差异更为明显,平均差异为5.72小时(p = 0.045)。米索前列醇组76.92%在24小时内分娩,而地诺前列酮组仅为70.4%。米索前列醇组的阴道分娩率更高(78%对71%)。在产时并发症和胎儿结局方面未发现显著差异。地诺前列酮组羊水粪染的情况更多见(23%对32%)。
25μg剂量的米索前列醇在促进宫颈成熟方面更具优势,显著缩短了引产至分娩间隔。在医院密切监测下应用时,其用于宫颈成熟是安全有效的。